With pipeline setbacks mounting, United snares priority voucher for inhaled formulation of PAH med Tyvaso

Despite a big lead in pulmonary arterial hyptertension, United Therapeutics is under the gun as it looks to stave off competitors and build a successful expansion over in oncology. So far, those results have been mixed. But now, United is on the cusp of adding a new formulation to its successful Tyvaso franchise that could spur growth.